| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CUEDC1 |
| Uniprot No | Q9NWM3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-386aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMTSLFRR SSSGSGGGGT AGARGGGGGT AAPQELNNSR PARQVRRLEF NQAMDDFKTM FPNMDYDIIE CVLRANSGAV DATIDQLLQM NLEGGGSSGG VYEDSSDSED SIPPEILERT LEPDSSDEEP PPVYSPPAYH MHVFDRPYPL APPTPPPRID ALGSGAPTSQ RRYRNWNPPL LGNLPDDFLR ILPQQLDSIQ GNAGGPKPGS GEGCPPAMAG PGPGDQESRW KQYLEDERIA LFLQNEEFMK ELQRNRDFLL ALERDRLKYE SQKSKSSSVA VGNDFGFSSP VPGTGDANPA VSEDALFRDK LKHMGKSTRR KLFELARAFS EKTKMRKSKR KHLLKHQSLG AAASTANLLD DVEGHACDED FRGRRQEAPK VEEGLREGQ |
| 预测分子量 | 45 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是模拟生成的关于CUEDC1重组蛋白的参考文献示例(请注意这些文献为虚构，仅供参考格式和内容方向)：
---
1. **文献名称**：*CUEDC1重组蛋白在NF-κB信号通路中的调控作用*
**作者**：Zhang L, et al.
**摘要**：本研究通过重组表达CUEDC1蛋白，发现其通过CUE结构域与IKKγ相互作用，促进NF-κB通路的负调控，抑制炎症反应，并可能影响肿瘤细胞凋亡。
2. **文献名称**：*CUEDC1重组蛋白的结构解析及其泛素结合机制*
**作者**：Wang Y, et al.
**摘要**：利用X射线晶体学解析CUEDC1重组蛋白的三维结构，揭示其CUE结构域与泛素分子的结合模式，为开发靶向泛素化通路的药物提供理论基础。
3. **文献名称**：*CUEDC1在卵巢癌细胞中的功能及其重组蛋白的体外验证*
**作者**：Chen H, et al.
**摘要**：通过重组CUEDC1蛋白的过表达实验，证明其通过下调ERα稳定性抑制卵巢癌细胞增殖，提示其作为潜在治疗靶点的价值。
---
**建议**：实际研究中请通过PubMed、Google Scholar等平台，以关键词“CUEDC1 recombinant protein”“CUEDC1 ubiquitination”等检索最新文献，或查阅《Journal of Biological Chemistry》《Oncogene》等期刊的相关研究。
CUEDC1 (CUE domain-containing protein 1) is a member of the CUE domain protein family, characterized by the presence of a conserved CUE domain that facilitates interactions with ubiquitinated proteins. This domain, typically spanning ~40 amino acids, enables CUEDC1 to participate in ubiquitin-dependent regulatory pathways, including protein degradation, trafficking, and signal transduction. The protein is implicated in diverse cellular processes such as cell cycle regulation, immune response modulation, and apoptosis. Studies suggest its involvement in key signaling pathways, including NF-κB and estrogen receptor (ER) pathways, where it may act as a scaffold or adaptor to regulate downstream effectors.
Recombinant CUEDC1 protein, produced via heterologous expression systems (e.g., E. coli or mammalian cells), retains functional domains critical for biochemical and structural studies. Its production enables researchers to explore molecular interactions, enzymatic kinetics, and structural conformations in vitro. CUEDC1 has garnered attention in cancer research due to its dysregulation in tumors, where it may influence therapeutic resistance by modulating proteasomal degradation of oncoproteins or tumor suppressors. In neurobiology, it has been linked to synaptic plasticity and neurodegenerative disorders, potentially through ubiquitin-mediated protein homeostasis.
Despite progress, mechanistic details of CUEDC1’s roles remain partially unresolved. Recombinant protein tools are pivotal for elucidating its binding partners, post-translational modifications, and context-dependent functions. Current research leverages these tools to identify small-molecule modulators targeting CUEDC1-ubiquitin interactions, with therapeutic potential in cancer and inflammation. Challenges include understanding tissue-specific expression patterns and reconciling conflicting data on its pro- versus anti-apoptotic effects. Further characterization of recombinant CUEDC1 is expected to clarify its regulatory networks and translational relevance.
×
